The cluster is mixed: large equity grants to executives suggest alignment, but the $7.1M in open-market sales by senior officers post-acquisition warrants monitoring. Watch for any further insider selling or credit rating actions given the increased leverage from the Kashiv deal.
Price Chart
Executive Summary
Amneal Pharmaceuticals insiders sold $7.1M in stock over a 7-day window, including the EVP of Legal and an Executive VP, just days after the company closed a $375M acquisition of Kashiv BioSciences funded partly by new debt. The insider sales follow a large equity grant to the co-CEOs and other executives, suggesting a mix of liquidity needs and possible caution post-deal. The cluster is notable for its size and timing relative to the acquisition, but the sales are not proportionally large enough relative to market cap to be highly bearish on their own.
Key Financial Metrics
Key Facts
- Insiders sold $7.1M in stock over 7 days, led by EVP Daly ($3.65M) and EVP Shah ($2.56M)
- Sales occurred 2-3 days after Amneal closed its $375M acquisition of Kashiv BioSciences
- Co-CEOs Patel Chintu and Patel Chirag received 6.38M shares each in equity grants on the deal closing date
- Total insider sales represent ~0.2% of Amneal's $3.6B market cap — modest but notable
- The company added $350M in incremental term loan debt to fund the Kashiv acquisition
Financial Impact
Insider sales of $7.1M represent ~0.2% of market cap; the $375M acquisition added $350M in new debt, increasing leverage
Risk Factors
- Insider sales may signal caution about near-term integration risks or leverage from the Kashiv acquisition
- The $350M term loan increases financial risk if biosimilar revenue ramp is slower than expected
- Large equity grants dilute existing shareholders, though they align management with long-term value creation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-AMRX-1786775211080 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K/A | $20.38 | awaiting T+60 | — | $21.02 (+3.14%) |
Sep 18, 2026 5w ago | Press Release | $20.16 | awaiting T+60 | — | $21.02 (+4.27%) |
Aug 16, 2026 10w ago | Institutional Cluster | $18.42 | awaiting T+60 | — | $21.02 (+14.12%) |
Aug 14, 2026 10w ago | Insider Cluster | $18.42 | awaiting T+60 | — | $21.02 (+14.12%) |
Aug 13, 2026 10w ago | Insider Cluster | $18.15 | awaiting T+60 | — | $21.02 (−15.81%) |
Aug 10, 2026 11w ago | 8-K | $17.10 | awaiting T+60 | — | $21.02 (+22.92%) |
Jul 30, 2026 12w ago | DEFA14A | $18.50 $20.38 | ▲ +10.16% | ▲ +7.70% | $21.02 (+13.62%) |
Jul 17, 2026 14w ago | Press Release | $17.85 $20.03 | ▲ +12.21% | ▲ +7.53% | $21.02 (+17.76%) |
Jun 29, 2026 17w ago | DEFM14A | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.02 (+21.57%) |
Jun 29, 2026 17w ago | Press Release | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.02 (+21.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers